Clinical Trials Logo

Melanoma Stage Iv clinical trials

View clinical trials related to Melanoma Stage Iv.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04904120 Completed - Melanoma (Skin) Clinical Trials

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

TIMAR1
Start date: March 5, 2021
Phase: Phase 1
Study type: Interventional

The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1 receptor (MC1R) by SPECT/CT and PET/CT imaging modalities respectively.

NCT ID: NCT04154163 Completed - Ovarian Cancer Clinical Trials

Appropriate Dosing to Optimise Personalised Cancer Treatments

ADOPT
Start date: January 10, 2020
Phase:
Study type: Observational

This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted treatment with BRAF and MEK inhibitors.

NCT ID: NCT03879395 Completed - Melanoma Stage Iv Clinical Trials

Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study

SurgMelMet
Start date: January 1, 2010
Phase:
Study type: Observational

The aim is to conduct a single centre retrospective study of all patients with stage IV melanoma that underwent surgery for metastases at Sahlgrenska University Hospital between 2010-01-01 and 2018-12-31. Pre- and postoperative data will be collected from digital medical records, the Swedish Cancer Registry, the Swedish Cause of Death Register as well as from the national Swedish cancer patient database (INCA). If needed, patient records will be collected from other hospitals. Results will be presented in written format as a summary and analysis of the characteristics of the cases operated on during the inclusion period. The aim is to identify predictive and prognostic factors for outcome and complications in the surgical treatment of stage IV metastatic melanoma.

NCT ID: NCT03620019 Completed - Melanoma Clinical Trials

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Start date: September 25, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1 (PD1) agent (pembrolizumab or nivolumab) in patients with unresectable Programmed death-1 or Programmed death ligand 1 (PD-1/PD-L1) inhibitor-naïve regional and distant metastatic melanoma (The American Joint Committee on Cancer (AJCC) stage III/IV). The pharmacodynamic and antitumor effects will be investigated by performing translational research on peripheral blood and tumor tissue collected before and during denosumab alone and in combination with anti-PD-1 treatment.

NCT ID: NCT03153085 Completed - Melanoma Stage IV Clinical Trials

A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma

Start date: May 25, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if TBI-1401(HF10) in combination with ipilimumab is effective in Japanese patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.